BioReliance® Biopharmaceutical Safety Testing Services

Overview

BioReliance® Biopharmaceutical Safety Testing Services—now operated under Merck’s global biologics quality and compliance infrastructure—deliver comprehensive, regulatory-grade safety assessment solutions for biopharmaceuticals, cell and gene therapies, vaccines, and recombinant proteins. These services are grounded in internationally recognized biological safety testing principles, including viral clearance validation, adventitious agent detection (e.g., PCR-based assays for retroviruses, mycoplasma, and bovine viral diarrhea virus), endotoxin quantification (LAL/kinetic chromogenic), sterility assurance (USP , Ph. Eur. 2.6.1), and host cell protein (HCP) and DNA residual analysis. Designed to support development from preclinical candidate selection through commercial manufacturing and post-approval lifecycle management, the service portfolio aligns with ICH Q5A(R2), Q5B, Q5D, and Q9 guidance, as well as FDA, EMA, PMDA, and Health Canada expectations for biologics licensure.

Key Features

• End-to-end safety testing strategy development, including risk-based assay selection, protocol design, and acceptance criteria justification in accordance with ICH and regional regulatory frameworks
• Viral clearance studies performed under GMP-compliant conditions using validated spiking models (e.g., MuLV, X-MuLV, PRV, Reo-3) across upstream and downstream unit operations
• Comprehensive adventitious agent testing per USP , EP 2.6.7, and JP XVII, including in vitro cell culture assays, PCR panels, and next-generation sequencing (NGS)-based broad-spectrum detection
• Residual impurity characterization—including HCP ELISA (species-specific), residual DNA quantification (qPCR), and process-related impurities—conducted with method verification per ICH Q2(R2)
• Integrated analytical method development and transfer support, with full documentation packages compliant with FDA 21 CFR Part 11 and EU Annex 11 requirements
• Dedicated regulatory consultation for CMC sections of IND/IMPD, BLA/MAA submissions, and responses to agency queries

Sample Compatibility & Compliance

The BioReliance service platform accepts a wide range of sample types—including bulk drug substance, drug product formulations, raw materials (e.g., serum, trypsin, growth factors), cell banks (MCB/WCB), and purification intermediates—from mammalian (CHO, HEK293), microbial (E. coli, yeast), and novel modalities (lentiviral vectors, CAR-T lysates). All testing is conducted in ISO/IEC 17025-accredited laboratories and cGMP-compliant facilities certified by FDA, EMA, and UK MHRA. Study reports include full audit trails, raw data archives, and metadata structured for GLP/GMP traceability. Documentation conforms to ALCOA+ principles and supports inspection readiness for FDA pre-approval inspections (PAIs), EMA GMP inspections, and WHO prequalification audits.

Software & Data Management

Testing workflows are managed via a validated Laboratory Information Management System (LIMS) integrated with electronic laboratory notebooks (ELN) and document management systems (DMS). All analytical data—including chromatograms, electropherograms, qPCR amplification plots, and NGS read alignments—are captured, timestamped, and stored with role-based access control. Electronic signatures comply with 21 CFR Part 11 and EU Annex 11; audit trails are immutable and reviewable down to the field-level change. Raw datasets and final reports are delivered in secure, encrypted portals with configurable retention policies aligned with ICH M4 and regional regulatory retention mandates (e.g., FDA 21 CFR Part 312.57, EMA Guideline on Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use).

Applications

• Supporting IND/CTA submissions with fully documented safety testing packages for Phase I–III clinical trial materials
• Enabling BLA/MAA filings through integrated viral clearance validation reports and comparability protocols for process changes
• Facilitating tech transfer between contract manufacturing organizations (CMOs) and sponsors via standardized assay protocols and reference standard coordination
• Maintaining post-approval compliance through routine lot release testing, stability-indicating safety assays, and periodic revalidation per ICH Q5A(R2) Section 5.3
• Addressing emerging modalities: safety testing strategies for mRNA-LNPs, AAV vectors, allogeneic cell therapies, and bispecific antibodies incorporating orthogonal detection methods

FAQ

Are BioReliance safety testing services conducted under cGMP or GLP conditions?
Testing for lot release, viral clearance, and regulatory submission support is performed under cGMP conditions per 21 CFR Parts 210/211 and EU GMP Annex 1. Non-clinical exploratory studies may be conducted under GLP where scientifically appropriate.
Can BioReliance support testing for novel biologics not covered by existing pharmacopoeial monographs?
Yes—method development and validation are offered for non-standard analytes, including bespoke qPCR assays, custom ELISAs, and orthogonal NGS workflows, all aligned with ICH Q5A(R2) and Q2(R2) expectations.
How long does a typical viral clearance study take from initiation to final report delivery?
Standard viral clearance programs require 12–16 weeks, depending on vector complexity, number of process steps evaluated, and client responsiveness during protocol review and data interpretation phases.
Is raw data provided with the final report?
Yes—all primary data files (e.g., .csv, .tdms, .ab1, .bam), instrument logs, and metadata are archived and made available upon request in accordance with sponsor data ownership agreements and regulatory retention timelines.
Do BioReliance services support global regulatory submissions beyond FDA and EMA?
Yes—testing strategies and reporting formats are adaptable to PMDA, Health Canada, TGA, ANVISA, and SFDA/NDCA requirements, with local regulatory consultants available for jurisdiction-specific alignment.